Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR4 | P46093 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26388302 | 0.86 | ALDH1A1 (0.44) | GPR119BACE1TP53 | |
| SCHEMBL29768897 | 0.84 | GPR119 (0.39) | GPR4GPR119NAMPTKDM4EPKM | |
| SCHEMBL22322096 | 0.78 | KDM4E (0.50) | GPR119KDM4EPKMTP53 | |
| SCHEMBL24622431 | 0.78 | NR1H2 (0.50) | GPR119NAMPTKDM4EPKMNR1H2 | |
| SCHEMBL7658016 | 0.77 | CNR1 (0.44) | GPR119HDAC1 | |
| SCHEMBL24622416 | 0.77 | NR1H2 (0.56) | GPR119NAMPTKDM4EPKMHDAC1 | |
| SCHEMBL6823295 | 0.76 | GPR119 (0.48) | GPR119NAMPTKDM4EPKMTP53 | |
| SCHEMBL23933137 | 0.73 | USP2 (0.39) | GPR119NR1H2DDB1CRBN | |
| SCHEMBL21590800 | 0.71 | USP2 (0.41) | GPR119NR1H2 | |
| SCHEMBL21590661 | 0.71 | USP2 (0.41) | GPR119NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4271387-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF | Immunext, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT INC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT INC (US) | 2023-10-05 | — | — | US | disclosed |
| CN-116096413-A | Anti-human VISTA antibodies and uses thereof | 伊穆奈克斯特股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4136118-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Immunext, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022150637-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | IMMUNEXT, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150637-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | IMMUNEXT, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2021216913-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | CD47, CLTA, FCGR2A | GPR4 1960/4885GPR119 2146/4885NAMPT 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.